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The effect of the i.c.v. administration of pertussis toxin 
(PTX) and antisense oligodeoxynucleotides directed against 
the 
 

 
 subunit of different Gi-proteins (anti-Gi
 

 
1
 
, anti-Gi
 

 
2
 
, 
anti-Gi
 

 
3
 
, anti-Go
 

 
1
 
, anti-Go
 

 
2
 
) on the antidepressant-like 
effect induced by amitriptyline and clomipramine, was 
evaluated in the mouse forced swimming test, an animal 
model of depression. The administration of amitriptyline 
 
(15 mg kg
 

 
1
 
 s.c.) and clomipramine (25 mg kg
 

 
1
 
 s.c.) 
produced an increase in the mobility time that was 
prevented by PTX (0.25 
 

 
g per mouse i.c.v.), administered 
11 days before the mouse forced swimming test. Anti-Gi
 

 
1
 
 
(12.5 
 

 
g per mouse i.c.v.), anti-Gi
 

 
2
 
 (12.5 
 

 
g per mouse 
i.c.v.), anti-Gi
 

 
3
 
 (6.25 
 

 
g per mouse i.c.v.), and anti-Go
 

 
1
 
 
(6.25 
 

 
g per mouse i.c.v.), administered 24 and 18 h before 
the training session, prevented the amitriptyline and 
clomipramine increase of the mobility time. By contrast, 
pretreatment with anti-Go
 

 
2
 
 (1.56-12.5 
 

 
g per mouse 
i.c.v.) never modified the antidepressant-like effect induced 
by the two investigated compounds. At the highest effective 
doses, none of the compounds used impaired motor 
coordination, as revealed by the rota-rod test, nor modified 
spontaneous motility and inspection activity, as revealed by 
the hole-board test. These results suggest the important role 
played by Gi
 
1
 
, Gi
 
2
 
, Gi
 
3
 
, and Go
 
1
 
 protein subtypes and the 
lack of involvement by Go
 
2
 
 protein subtype in the 
transduction mechanism responsible for the antidepressant-
like effect produced by amitriptyline and clomipramine. 
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For the past several decades, antidepressant drugs have
been widely used in the treatment of clinical depression
and other psychiatric disorders. Several distinct pharmaco-
logical compounds show therapeutic efficacy. These in-
clude monoamine oxidase inhibitors, tricyclic compounds,
selective serotonin and norepinephrine reuptake inhibi-
tors, as well as some atypical drugs. Numerous studies
have examined the effects of antidepressants on neu-
rotransmitter metabolism, turnover, and receptor sensi-
tivity and several theories on their mechanism of ac-
tion have been proposed. These include the inhibition
of monoamine transporter activity in presynaptic mem-
 
branes (Schildkraut 1965), downregulation of 
 

 
-adreno-
ceptors (Mazzola-Pomietto et al. 1994), alteration at cholin-
ergic, dopaminergic or GABAergic receptors (Henringer
and Charney 1987). However, the molecular mechanism
of action underlying the therapeutic effect of antide-
pressants is still unclear.
Despite their diversity, these treatments subserve the
same final clinical effect. Therefore, the possibility that
these diverse agents converge on a single postrecepto-
rial target evoked a great research interest. Since most
neurotransmitter receptors and neuromodulators are
coupled to intracellular effectors through G-proteins
(Birnbaumer 1990), recent studies searching for a com-
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mon mechanism of antidepressant action have focused
on G-proteins as a potential target of such action.
G-proteins are a ubiquitous family of proteins that
play a crucial role in transducing extracellular signals to
cellular targets, thus transmitting messages from cell
surface receptors to cellular effectors including adeny-
late cyclase, phospholipase C and ion channels (Sprang
1997). G-proteins are heterotrimeric molecules with 
 

 
, 
 

 
and 
 

 
 subunits. The 
 

 
 subunits can be classified into
families, depending on whether they are targets for
cholera toxin (Gs), pertussis toxin (PTX) (Gi and Go) or
neither (Gq and G
 
12
 
) (Simon et al. 1991). A growing
body of evidence suggests that G-proteins are the mo-
lecular target of many antidepressants. Menkes et al.
(1983) first reported that long-term administration of
various antidepressants enhanced guanylyl-5
 

 
-imido-
diphosphate and fluoride-stimulated adenylyl cyclase
activity in rat cortex and hypothalamus membranes
suggesting Gs-protein as target for antidepressant ac-
tion. These initial findings involving the stimulation of
adenylyl cyclase via Gs-proteins after antidepressant
treatment was further supported by later studies
(Yamaoka et al. 1988; Ozawa and Rasenick 1989; Ka-
mada et al. 1999). Furthermore, increased expression
and activity of cAMP response element binding protein
has been demonstrated in various rat brain regions,
such as hippocampus, cerebral cortex, amygdala, and
hypothalamus (Nibuya et al. 1996; Duman et al. 1997;
Thome et al. 2000). Recently, it has been suggested that
chronic treatment with antidepressant drugs induces
modification of the coupling between Gs-coupled re-
ceptors and adenylate cyclase in C6 glioma cells (Do-
nati et al. 2001).
Pertussis toxin-sensitive G-proteins (G
 
i
 
-proteins)
represent the most widespread modulatory signaling
pathway in neurones (Holtz et al. 1986) and are respon-
sible for inhibition of adenylate cyclase activity and
modulation of several K
 

 
 and Ca
 
2
 

 
 channels (Hille 1994;
Sprang 1997). Contrary to Gs-proteins, the role of Gi-
proteins in the mechanism of action of antidepressant
drugs is more controversial. Chronic treatment with an-
tidepressant drugs has been reported to produce a re-
duction of Gi
 

 
 and an increase of the Go
 

 
 protein levels
(Lesch et al. 1991; Lesch and Manji 1992; Raap et al. 1999)
in various regions of rat brain, including neostriatum,
hypothalamus, frontal cortex and midbrain. By con-
trast, no alteration of Gi
 

 
 and Go
 

 
 protein and mRNA
levels in rat brain (cortex, hippocampus, cerebellum)
was observed after chronic treatment with tricyclic anti-
depressants (TCA) and monoamine oxidase inhibitors
(Li et al. 1993; Chen and Rasenick 1995; Emamghoreishi
et al. 1996; Dwivedi and Pandey 1997).
In light of these controversial data, the aim of the
present study was to further elucidate the role of the Gi-
protein family in the mechanism of action of antide-
pressant drugs. In particular, we used antisense oligo-
nucleotides (aODN) against the 
 

 
 subunits of the Gi
 
1
 
,
Gi
 
2
 
, Gi
 
3
 
, Go
 
1
 
 and Go
 
2
 
 proteins in order to determine the
role of each subtype in the antidepressant-like effect in-
duced by amitriptyline and clomipramine in the mouse
forced swimming test. In order to exclude that the ef-
fects produced by aODN treatments were due to the in-
duction of side effects, some additional behavioral tests
(rota-rod, hole-board) were performed.
 
METHODS
Animals
 
Male Swiss albino mice (23–25 g) from the Morini (San
Polo d’Enza, Italy) breeding farm were used. Fifteen
mice were housed per cage (26 
 
	
 
 41 cm). The cages
were placed in the experimental room 24 h before the
test for acclimatization. The animals were fed a stan-
dard laboratory diet and tap water ad libitum and kept
at 23 
 


 
 1
 

 
C with a 12 h light/dark cycle, light on at 7
 
A
 
.
 
M
 
. All experiments were carried out in accordance
with the Guide for the Care and Use of Laboratory Ani-
mals as adopted and promulgated by the National In-
stitutes of Health.
 
Intracerebroventricular Injection Technique
 
Intracerebroventricular (i.c.v.) administration was per-
formed under ether anesthesia, according to the method
described by Haley and McCormick (1957). Briefly,
during anesthesia, mice were grasped firmly by the
loose skin behind the head. A 0.4 mm external diame-
ter, hypodermic needle attached to a 10 
 

 
l syringe was
inserted perpendicularly through the skull and no more
than 2 mm into the brain of the mouse, where 5 
 

 
l were
then administered. The injection site was 1 mm to the
right or left from the midpoint on a line drawn through
to the anterior base of the ears. Injections were per-
formed into the right or left ventricle randomly. To as-
certain that the drugs were administered exactly into
the cerebral ventricle, some mice (20%) were injected
with 5 
 

 
l of diluted 1:10 India ink and their brains ex-
amined macroscopically after sectioning. The accuracy
of the injection technique was evaluated and the per-
centage of correct injections was determined to be 95.
 
Forced Swimming Test
 
The forced swimming test used was the same as de-
scribed by Porsolt et al. (1977). Briefly, mice were
dropped individually into glass cylinders (height: 25 cm,
diameter: 10 cm) containing 6 cm of water maintained
at 22–23
 

 
C and left there for 6 min. A mouse was judged
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to be immobile when it floated in the water, in an up-
right position, and made only small movements to keep
its head above water. The duration of mobility was re-
corded during the last 4 min of the 6-min test. An in-
crease in the duration of mobility is indicative of an an-
tidepressant-like effect. The test was performed 24–18 h
after i.c.v. injections of ODNs, 11 days after PTX admin-
istration, 30 min after tricyclic antidepressant injection.
 
Hole-board Test
 
The hole-board test consisted of a 40 cm square plane
with 16 flush mounted cylindrical holes (3 cm diameter)
distributed 4 by 4 in an equidistant grid. Mice were
placed on the center of the board one by one and al-
lowed to move about freely for a period of 10 min each.
Two electric eyes, crossing the plane from mid-point to
mid-point of opposite sides, thus dividing the plane
into four equal quadrants, automatically signaled the
movement of the animal (counts in 5 min) on the sur-
face of the plane (locomotor activity). Miniature photo-
electric cells, in each of the 16 holes, recorded (counts in
5 min) the exploration of the holes (exploratory activity)
by the mice. The test was performed 18–24 h after the
i.c.v. injections of degenerate ODN (dODN) or aODN,
11 days after administration of PTX. 12–15 mice per
group were tested.
 
Rota-rod Test
 
The apparatus consisted of a base platform and a rotat-
ing rod with a diameter of 3 cm and a non-slippery sur-
face. The rod was placed at a height of 15 cm from the
base. The rod, 30 cm in length, was divided into five
equal sections by six disks. Thus, up to five mice were
tested simultaneously on the apparatus, with a rod ro-
tating speed of 16 rpm. The integrity of motor coordina-
tion was assessed on the basis of the number of falls
from the rod in 30 s according to Vaught et al. (1985).
Those mice scoring less than three and more than six
falls in the pretest were rejected (20%). The perfor-
mance time was measured before (pretest) and 15, 30
and 45 min after s.c. treatment. Animals were i.c.v. pre-
treated 24–18 h prior to the test with degenerate ODN
(dODN) or aODN or 11 days before the test with PTX.
12–15 mice per group were tested.
 
Antisense Oligonucleotides
 
The sequences of the antisense oligonucleotides used in
the present study are shown in Table 1.
Phosphodiester ODNs protected from terminal
phosphorothioate double substitution (capped ODNs)
against possible exonuclease-mediated degradation
were used (Tib Molbiol, Genova, Italy). A 33-mer fully
degenerated ODN (dODN) 5
 

 
-N*N*N NNN NNN
NNN NNN NNN NNN NNN NNN NNN N*N*N -3
 

 
(where N is G, C, A, or T) and a 25-mer fully degener-
ated ODN (dODN) 5
 

 
-N*N*N NNN NNN NNN NNN
NNN NNN NN*N *N -3
 

 
 (where N is G, C, A, or T)
were used as a control respectively for anti-Gi
 

 
 and
anti-Go
 

 
. ODNs were vehiculated intracellularly by an
artificial cationic lipid (DOTAP, Sigma) to enhance both
uptake and stability, as described previously (Capacci-
oli et al. 1993). aODN or dODN were preincubated at
37
 

 
C for 30 min with 13 
 

 
M DOTAP and supplied to
mice by i.c.v. injection of 5 
 

 
l solution 18 and 24 h prior
to the behavioral tests. All ODNs were previously char-
acterized by in vitro (immunoblotting) and in vivo (tail
flick) experiments (Kleuss et al. 1991; Raffa et al. 1994;
Sanchez-Blazquez et al. 1995; Sanchez-Blazquez and
Garzon 1998). We also confirmed the aODN effect on
G
 

 
 protein levels by performing immunoblotting ex-
periments. We observed a statistically significant reduc-
tion of the expression of Gi
 

 
1
 
, Gi
 

 
2
 
, Gi
 

 
3
 
, Go
 

 
1
 
 and
Go
 

 
2
 
 subunits after aODN treatment in comparison
with mice treated with dODN (data not shown).
 
Drugs
 
The following drugs were used: pertussis toxin (RBI);
clomipramine hydrochloride amitriptyline hydrochlo-
ride, DOTAP (Sigma); D-amphetamine hydrochloride
(De Angeli). All drugs were dissolved in isotonic (NaCl
0.9%) saline solution immediately before use, except for
pertussis toxin which was dissolved in a water solution
containing 0.01 M sodium phosphate buffer, pH 
 
 
 
7.0,
with 0.05 M sodium chloride. Drug concentrations were
prepared in such a way that the necessary dose could
 
Table 1.
 
Sequences of Antisense Oligonucleotides
 
aODN Sequences
 
anti-Gi
 

 
1
 
5
 

 
- G*C*T GTC CTT CCA CAG TCT CTT TAT GAC GCC G*G*C -3
 

 
anti-Gi
 

 
2
 
5
 

 
- A*T*G GTC AGC CCA GAG CCT CCG GAT GAC GCC C*G*A -3
 

 
anti-Gi
 

 
3
 
5
 

 
- G*C*C ATC TCG CCA TAA ACG TTT AAT CAC GCC T*G*C -3
 

 
anti-Go
 

 
1
 
5
 

 
- A*G*G CAG CTG CAT CTT CAT AGG TG*T *T -3
 

 
anti-Go
 

 
2
 
5
 
- G*A*G CCA CAG CTT CTG TGA AGG CA*C *T -3
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be administered in a volume of 10 ml kg1 by s.c. injec-
tion or 5 l per mouse by i.c.v. injection.
Statistical Analysis
All experimental results are given as the mean 
 SEM
Analysis of variance (ANOVA), followed by Fisher’s
Protected Least Significant Difference (PLSD) proce-
dure for post-hoc comparison, was used to verify sig-
nificance between two means. Data were analyzed with
the StatView software for the Macintosh, 1992 version.
p values of less than .05 were considered significant.
RESULTS
Effect of Pertussis Toxin on TCAs
Antidepressant-like Effect
Amitriptyline (15 mg kg1 s.c.) and clomipramine (25
mg kg1 s.c.), injected 30 min before the test, induced an
increase of the mobility time in the mouse forced swim-
ming test (Figure 1). Pretreatment with pertussis toxin
(PTX), injected i.c.v. at the dose of 0.25 g per mouse 11
days before the test, completely prevented the amitriptyline
and clomipramine antidepressant-like effect (Figure 1).
Effect of aODN against Gi Subunits on
TCA-induced Antidepressant-like Effect
The increase of mobility time induced by amitriptyline
(15 mg kg1 s.c.) and clomipramine (25 mg kg1 s.c.)
was prevented, in the mouse forced swimming test, by
pretreatment with the aODN against the  subunit of
the Gi proteins (Figures 2–4). Anti-Gi1 (3.12–12.5 g
per mouse i.c.v.) produced a dose-dependent antago-
nism of the TCA-induced antidepressant-like effect.
The dose of 3.12 g per mouse i.c.v. was completely in-
effective whereas the maximum effect was obtained at
12.5 g per mouse i.c.v. (Figure 2).
Similarly, anti-Gi2 at 3.12 g per mouse i.c.v. was
devoid of any effect; at 6.25 g per mouse i.c.v. partially
prevented the TCA effect, even if the statistical signifi-
cance was not reached, whereas the dose of 12.5 g per
mouse i.c.v. reduced the mobility time up to a value com-
parable to that produced by control animals (Figure 3).
The administration of an aODN against the  sub-
unit of the Gi3 proteins (1.56–6.25 g per mouse i.c.v.)
antagonized the increase of mobility time produced by
amitriptyline and clomipramine reaching its maximum
effect at 6.25 g per mouse i.c.v. (Figure 4). Anti-Gi1
(12.5 g per mouse i.c.v.), anti-Gi2 (12.5 g per mouse
i.c.v.), and anti-Gi3 (6.25 g per mouse i.c.v.) did not
produce any modification of the mobility time in the
mouse forced swimming test in comparison with i.c.v.
saline- (data not shown) and dODN-treated mice when
given alone (Figures 2–4).
Effect of aODN against Go Subunits on
TCA-induced Antidepressant-like Effect
Anti-Go1 (1.56-6.25 g per mouse i.c.v.) produced a dose-
dependent antagonism of the increase in the mobility
time of mice induced by both amitriptyline and clomi-
pramine. The maximum effect of anti-Go1 was reached
at the doses of 6.25 g per mouse i.c.v., concentration
that did not modify the mobility time of animals, in com-
parison with control group, when administered alone
(Figure 5). The administration of an aODN against the 
subunit of the Go2 proteins (1.56–12.5 g per mouse
i.c.v.), in contrast to anti-Go1, was unable to prevent
the TCA-induced antidepressant-like effect (Figure 6).
Effect of aODN against Gi and Go Subunits on 
Mouse Rota-rod and Hole-board Tests
It should be noted that the tricyclic antidepressants
(amitriptyline, clomipramine) and the aODNs under in-
vestigation elicited their modulatory effects on mobility
time in the forced swimming test without changing
gross behavior, motor coordination (as revealed by the
rota-rod test (Figure 7), spontaneous motility, or inspec-
tion activity, as revealed by the hole-board test (Table
Figure 1. Prevention by pertussis toxin (PTX) of amitrip-
tyline- and clomipramine-induced increase of the mobility
time in the mouse forced swimming test. The test was per-
formed 11 days after a single i.c.v. injection of vehicle or PTX
(0.25 g per mouse). Amitriptyline (15 mg kg1 s.c.) and clo-
mipramine (25 mg kg1 s.c.), were administered 30 min
before the test. Between 19 and 25 mice were tested. Vertical
lines represent SEM. *p  .05 in comparison with vehicle 
clomipramine, **p  .01 in comparison with vehicle  ami-
triptyline treated mice.
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2).] The doses of amitriptyline and clomipramine of re-
spectively 15 and 25 mg kg1 s.c. did not modify the
number of falls from the rotating rod in comparison
with saline-treated mice. Each group progressively re-
duced its number of falls because mice learned how to
balance on the rotating rod. Higher doses of amitrip-
tyline (30 mg kg1 s.c.) and clomipramine (45 mg kg1
s.c.) produced an increase in the number of falls indicat-
ing the presence of motor incoordination (Figure 7,
panel A). The motor coordination of mice pretreated
with aODN to Gi1 (12.5 g per mouse i.c.v.), Gi2 (12.5
g per mouse i.c.v.), Gi3 (6.25 g per mouse i.c.v.),
Go1 (6.25 g per mouse i.c.v.), and Go2 (12.5 g per
mouse i.c.v.) was evaluated by using the rota-rod test.
The number of falls of aODN-treated groups was com-
parable to that of the dODN-treated mice (Figure 7,
panel B). The spontaneous motility and exploratory ac-
tivity of mice was not modified by administration of
amitriptyline, clomipramine, PTX, and the above-men-
tioned aODNs as revealed by the hole-board test in
comparison with saline-, vehicle- and dODN-treated
mice (Table 2). In the same experimental conditions
Figure 2. Prevention by pretreatment
with an antisense oligonucleotide (aODN)
to the  subunit of Gi1-protein gene
(3.12–12.5 g per mouse i.c.v.) of ami-
triptyline (15 mg kg1 s.c.)- and clomi-
pramine (25 mg kg1 s.c.)-induced
antidepressant-like effect in the mouse
forced swimming test. The test was per-
formed 18–24 h after the i.c.v. injection
of degenerate ODN (dODN; 12.5 g per
mouse i.c.v.) or aODN. Between 16 and
23 mice were tested. Vertical lines rep-
resent SEM; the dose administered is
reported below each column. *p  .05,
**p  .01 in comparison with the corre-
sponding TCA.
Figure 3. Prevention by pretreatment
with an antisense oligonucleotide (aODN)
to the  subunit of Gi2-protein gene
(3.12–12.5 g per mouse i.c.v.) of ami-
triptyline (15 mg kg1 s.c.)- and clomi-
pramine (25 mg kg1 s.c.)-induced anti-
depressant-like effect in the mouse
forced swimming test. The test was
performed 18–24 h after the i.c.v. injec-
tion of degenerate ODN (dODN; 12.5
g per mouse i.c.v.) or aODN. Between
18 and 23 mice were tested. Vertical
lines represent SEM; the dose adminis-
tered is reported below each column.
*p  .05 in comparison with the corre-
sponding TCA.
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D-amphetamine (2 mg kg1 s.c.), used as the reference
drug, increased both parameters evaluated.
DISCUSSION
Signal transduction mechanisms involved in the antide-
pressant-like effect produced by amitriptyline and clo-
mipramine, two compounds belonging to the tricyclic
antidepressant class, have been investigated in the
mouse forced swimming test. The forced swimming
test is widely used to predict the antidepressant action
of drugs in humans. The mobility time of mice in this
test is increased by the majority of antidepressants in-
cluding tricyclic and atypical antidepressants, MAO in-
hibitors and 5-HT uptake inhibitors (Porsolt et al. 1977;
Bourin et al. 1991), and their effectiveness correlates sig-
nificantly with clinical potency (Willner 1984). However,
Figure 4. Prevention by pretreatment
with an antisense oligonucleotide (aODN)
to the  subunit of Gi3-protein gene
(1.56–6.25 g per mouse i.c.v.) of ami-
triptyline (15 mg kg1 s.c.)- and clomi-
pramine (25 mg kg1 s.c.)-induced
antidepressant-like effect in the mouse
forced swimming test. The test was
performed 18–24 h after the i.c.v. injec-
tion of degenerate ODN (dODN; 12.5 g
per mouse i.c.v.) or aODN. Between 16
and 21 mice were tested. Vertical lines
represent SEM; the dose administered
is reported below each column. *p 
.05, **p  .001 in comparison with the
corresponding TCA.
Figure 5. Prevention by pretreatment
with an antisense oligonucleotide (aODN)
to the  subunit of Go1-protein gene
(1.56–6.25 g per mouse i.c.v.) of ami-
triptyline (15 mg kg1 s.c.)- and clomi-
pramine (25 mg kg1 s.c.)-induced
antidepressant-like effect in the mouse
forced swimming test. The test was per-
formed 18–24 h after the i.c.v. injection
of degenerate ODN (dODN; 12.5 g per
mouse i.c.v.) or aODN. Between 15 and
22 mice were tested. Vertical lines rep-
resent SEM; the dose administered is
reported below each column. *p  .05,
**p  .001 in comparison with the corre-
sponding TCA.
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this animal model has also some drawbacks repre-
sented by the possibility to obtain some false positives
or negatives (Borsini and Meli 1988; Detke and Lucki
1996). Drugs enhancing motor activity, such as anticho-
linergics and antihistamines, may give a “false” posi-
tive effect in the forced swimming test and antidepres-
sants such as bupropion, nomifensine, and amineptine
would then be rejected since they increase motor activ-
ity (Borsini and Meli 1988).
Present results indicate that the activation of Gi pro-
teins is required for the induction of the antidepressant-
like effect produced by amitriptyline and clomipramine
in the mouse forced swimming test. The administration
of the investigated TCAs produced an increase of the
mobility time that was prevented by pretreatment with
pertussis toxin (PTX), a bacterial toxin produced by Bor-
detella pertussis that ADP-ribosylates and inactivates the
 subunit of Gi-protein family (Katada and Ui 1982).
These data confirm the important role played by Gi
proteins in the signal transduction mechanism acti-
vated by amitriptyline and clomipramine. Gi-proteins
represent the most widespread modulatory signaling
pathway in neurones (Holtz et al. 1986) and one of their
principal effect is the inhibition of adenylate cyclase ac-
tivity (Sprang 1997). It has been reported that chronic
treatment with several antidepressant drugs reduced
the cAMP production stimulated by forskolin or norad-
renaline (Mishra et al. 1980; Okada et al. 1986; Newman
et al. 1993), further supporting the hypothesis of the in-
volvement of this transduction system in the mecha-
nism of action of amitriptyline and clomipramine.
The Gi protein subfamily is composed of several dif-
ferent members: Gi1, Gi2, Gi3, Go1, and Go2 (Simon et al.
1991). Since PTX inactivates all members of the Gi-pro-
tein family, the role of each subtype was investigated
by pretreating animals with aODNs against the  sub-
units of the above-mentioned Gi and Go protein sub-
types. The inhibition of the expression of Gi1, Gi2,
Gi3 and Go1 produced a dose-dependent prevention
of TCA-induced increase of mobility time, whereas the
administration of an aODN against Go2 never exerted
any modification of amitriptyline and clomipramine ac-
tivity. These results indicate a differential involvement
of the Gi protein subtypes in the mechanism of action of
the investigated tricyclic antidepressants. In particular,
the integrity and functionality of Gi1, Gi2, Gi3, and Go1
proteins appears essential to produce the antidepres-
sant-like effect observed. The Gi3 and Go1 subtypes ap-
pear to be endowed with a prominent role since the
anti-Gi3 and anti-Go1 prevent the increase of mobility
time induce by both investigated TCAs at doses lower
than anti-Gi1 and anti-Gi2. By contrast, the Go2 subtype,
in these experimental conditions, appears not to be in-
volved implying that this subunit is not a major compo-
nent of transduction mechanisms leading to the ami-
triptyline and clomipramine antidepressant effect.
Chronic treatment with TCAs induces an increase in
the Go-protein levels in different rat brain regions, such
as frontal cortex, midbrain and hypothalamus (Lesch
et al. 1991; Lesch and Manji 1992). Moreover, Yama-
moto et al. (1992) reported that several TCAs, including
clomipramine, were able to increase, in a PTX-depen-
dent manner, the GTPase activity of Go proteins, puri-
fied from bovine brain membranes, indicating the
ability of these compounds to directly stimulate Go
proteins. Therefore, the important role played by Go1
proteins in amitriptyline and clomipramine antidepres-
sant-like activity could be due, at least in part, to a di-
Figure 6. Lack of effect of pretreat-
ment with an antisense oligonucleotide
(aODN) to the  subunit of Go2-protein
gene (1.56–12.5 g per mouse i.c.v.) on
amitriptyline (15 mg kg1 s.c.)- and clo-
mipramine (25 mg kg1 s.c.)-induced
antidepressant-like effect in the mouse
forced swimming test. The test was
performed 18–24 h after the i.c.v. injec-
tion of degenerate ODN (dODN; 12.5 g
per mouse i.c.v.) or aODN. Between 18
and 21 mice were tested. Vertical lines
represent SEM; the dose administered
is reported below each column. p 
.01 in comparison with control group.
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rect activation of the Go-protein subtype. Nevertheless,
it has been observed that chronic treatment with the an-
tidepressant drug imipramine decreases Go mRNA
levels in the rat hippocampus without modifying Gi
mRNA levels (Lason and Przewlocki 1993). This dis-
crepancy may stem from the heterogeneity of biological
sample used (rat frontal cortex, midbrain and hypothal-
amus, bovine brain membranes, rat hippocampus) sug-
gesting not only a differential effect of TCAs on differ-
ent cerebral areas, but also a different involvement of
the various brain regions in the induction of a depres-
sive state condition. However, a change in the mRNA
amount does not always imply defective protein func-
tion, but rather often appears to reflect compensatory
consequences. As matter of fact, even if no clear alter-
ation at mRNA Go protein level emerged, an increased
functionality of this transduction mechanism after anti-
depressant treatment has been evidenced. Concerning
Gi3, a reduction of this Gi-protein subtype has been ob-
served in the platelets from patients suffering from ma-
jor depression (Garcia-Sevilla et al. 1997). On these
bases we can hypothesize that amitriptyline and clomi-
pramine might exert their antidepressant effect by stim-
ulating Gi3 subtypes in order to balance its deficiency.
A role in the mechanism of action of TCAs played by
Gi2 proteins has been reported in humans. A reduced
coupling capability of 2-adrenoceptors, a receptor sub-
type involved in the induction of depression (Garcia-
Sevilla et al. 1999), with Gi2 proteins has been observed
in platelets from patients suffering from major depres-
sion. In consequence, an increase of Gi2 proteins has
been produced as a compensation mechanism (Karege
et al. 1996). In these patients, repeated treatment with
TCAs was reported to normalize the coupling of 2-
adrenoceptors with Gi2 proteins, inducing, consequently,
a reduction of Gi2 levels (Garcia-Sevilla et al. 1997; Kar-
ege et al. 1998). However, in our experimental condi-
tions, the involvement of the Gi1 and Gi2 subtypes in the
mechanism of action of amitriptyline and clomipramine
has been observed after administration of a dose of aODN
Figure 7. A. effect of amitriptyline and
clomipramine on motor coordination
in the mouse rota-rod test. Amitrip-
tyline (15–30 mg kg1 s.c.) and clomi-
pramine (25–45 mg kg1 s.c.) were
administered 30 min before the test. B.
effect of pretreatment with an aODN to
the  subunit of Gi1- (12.5 g per
mouse i.c.v.), Gi2- (12.5 g per mouse
i.c.v.), Gi3- (6.25 g per mouse i.c.v.),
Go1- (6.25 g per mouse i.c.v.), Go2-
(12.5 g per mouse i.c.v.) protein gene
on motor coordination in the mouse
rota-rod test. The test was performed
18–24 h after the i.c.v. injection of
dODN (12.5 g per mouse i.c.v.) or
aODN. Vertical lines represent SEM.
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two times higher than that necessary to produce a com-
parable effect with the anti-Gi3 and the anti-Go2. These
results, nevertheless, confirm the importance of the in-
volvement of these two Gi-protein subtypes in the anti-
depressant-like effect induced by the two TCAs, and
they also indicate a secondary role in comparison with
Gi3 and Go2. Moreover, chronic and subchronic treat-
ment with TCAs did not produce significant differences
on Gi1 and Gi2 protein and mRNA levels in rat brain (Li
et al. 1993; Lason and Przewlocki 1993; Emamghoreishi
et al. 1996; Dwivedi and Pandey 1997), further support-
ing the hypothesis of a minor role for these two Gi-pro-
tein subtypes.
The two investigated TCAs induced their antide-
pressant-like effect by acting centrally since pertussis
toxin and aODNs exerted their antagonistic effect after
i.c.v. administration. However, substances injected i.c.v.
can diffuse from the cerebral ventricles to the whole
brain. It is, therefore, difficult to define potential site of
actions of aODNs or pertussis toxin within the CNS.
Amitriptyline and clomipramine are inhibitors of the
reuptake of serotonin and noradrenaline, two neu-
rotransmitters involved in the modulation of mood.
Some serotonin receptor subtypes as well as 2 adreno-
ceptors (Birnbaumer 1990) are Gi-protein coupled re-
ceptors within the central nervous system. We cannot,
therefore, exclude the involvement of both neurotrans-
mission systems in the induction of the antidepressant-
like effects by the two investigated TCAs.
Pretreatment with aODN, at the highest effective
doses, did not produce any modification of mobility
time in the mouse forced swimming test. We can, there-
fore, conclude that the prevention of amitriptyline and
clomipramine antidepressant-like effect is not due to a
depressant-like effect exerted by these treatments. Fur-
thermore, pretreatment with dODN, used as the refer-
ence ODN, never modified the increase of mobility time
induced by the two investigated TCAs in comparison
with saline-treated animals (data not shown), which ex-
cludes the possibility of a sequence-independent effect
induced by the aODNs.
Numerous hormones and neurotransmitters activate
the Gi-protein system. The administration of PTX and
aODN against the  subunits of Gi proteins could in-
duce side effects that make the interpretation of the re-
sults difficult. Furthermore, since drugs that modify
motor activity may give false positive or negative effect,
it is suitable to carry out a test to check this aspect, in
parallel with forced swimming test. The highest doses
of the drugs used in the present work were the maxi-
mum that did not produce behavioral side effects.
The tricyclic antidepressants amitriptyline and clomi-
pramine, as well as ODNs, at the highest doses used,
did not modify animal’s gross behavior. All the sub-
stances used were tested on the rota-rod test before the
forced swimming test was performed, to make sure that
they did not influence the normal motor coordination
of the mice. Since ataxic mice are not able to coordinate
movements and thus fall from the rotating rod, while
excited animals tend to jump off the rod, the good per-
formance on the rod by mice in the present study indi-
cates the results obtained with the forced swimming
test are not due to altered motor activity induced by
substances at the doses used. Furthermore, not only al-
tered motor coordination but also a modified spontane-
ous motility could lead to a misinterpretation of the
results obtained in the forced swimming test. An influ-
ence of the substances used on spontaneous motility
has, therefore, been excluded by using the hole-board
test. Moreover, drugs which have a known psychostim-
Table 2. Lack of Effect on Spontaneous Motility and Inspection Activity by 
Amitriptyline, Clomipramine, PTX, dODN and aODNs in the Mouse Hole-board Test.
Pre-Treatment (i.c.v.) Treatment (s.c.)
Counts in 5 min
spontaneous motility inspection activity
Vehicle Saline 37.8 
 5.9 63.4 
 6.7
PTX 0.25 g Saline 35.1 
 4.8 65.3 
 7.2
Saline Saline 36.8 
 4.3 63.1 
 5.1
DOTAP 13 M Saline 37.8 
 3.1 61.9 
 6.1
dODN 12.5 g Saline 38.7 
 3.6 61.7 
 5.6
Anti-Gi1 12.5 g Saline 45.2 
 4.2 65.7 
 3.3
Anti-Gi2 12.5 g Saline 37.9 
 3.8 61.4 
 4.4
Anti-Gi3 6.25 g Saline 41.9 
 4.7 63.3 
 7.8
Anti-Go1 6.25 g Saline 39.4 
 4.5 62.9 
 6.5
Anti-Go2 12.5 g Saline 34.1 
 2.8 59.7 
 6.0
Saline Amitriptyline 15 mg kg1 36.0 
 4.5 62.0 
 6.1
Saline Clomipramine 25 mg kg1 36.0 
 4.5 62.0 
 6.1
Saline Amphetamine 2 mg kg1 73.2 
 7.1** 104.8 
 12.0**
Pertussis toxin (PTX) and ODNs were injected respectively 11 days and 24-18 h before the test. **p  0.01 in
comparison with saline-saline treated mice.
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ulant effect, like ()-amphetamine and caffeine, at the
same doses at which they are able to increase the time
of mobility in the rat forced swimming test, also show a
significant increased motor activity in an open field
(Porsolt et al. 1978).
In conclusion, our results evidence the important
role played by Gi1, Gi2, Gi3, and Go1, but not by
Go2, in the anti-immobility effect induced by amitrip-
tyline and clomipramine.
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